Public funding issues, the “broken commercial market”, and challenges in securing investment are the key limiting factors when it comes to the development of new therapies and other solutions to antimicrobial resistance (AMR), a conference has heard.
“SMEs and biotechs in this space really are the innovation engine,” said Deborah O’Neil, chief executive of NovaBiotics, a clinical-stage...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?